CeriBell (CBLL) to Release Earnings on Tuesday

CeriBell (NASDAQ:CBLL) is projected to announce its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect CeriBell to post earnings of ($0.43) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

CeriBell Stock Down 0.9%

Shares of NASDAQ:CBLL opened at $19.77 on Tuesday. The business has a 50-day moving average price of $21.39 and a 200 day moving average price of $15.91. CeriBell has a 12-month low of $10.01 and a 12-month high of $26.04. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $733.47 million, a price-to-earnings ratio of -13.09 and a beta of 1.03.

Insider Activity at CeriBell

In other news, CEO Xingjuan Chao sold 79,000 shares of CeriBell stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $21.27, for a total value of $1,680,330.00. Following the completion of the transaction, the chief executive officer owned 741,248 shares in the company, valued at approximately $15,766,344.96. This trade represents a 9.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Rebecca B. Robertson sold 2,500 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $21.89, for a total transaction of $54,725.00. Following the completion of the sale, the director directly owned 19,576 shares in the company, valued at approximately $428,518.64. This represents a 11.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 369,656 shares of company stock worth $7,281,615 over the last quarter. 20.10% of the stock is currently owned by insiders.

Institutional Trading of CeriBell

Institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd boosted its position in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell in the third quarter valued at approximately $33,000. Tower Research Capital LLC TRC increased its stake in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in CeriBell during the third quarter worth approximately $135,000. Finally, New York State Common Retirement Fund boosted its holdings in shares of CeriBell by 148.6% in the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after buying an additional 5,200 shares in the last quarter.

Analyst Upgrades and Downgrades

CBLL has been the topic of several recent analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Canaccord Genuity Group lifted their price objective on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. Finally, Raymond James Financial initiated coverage on shares of CeriBell in a research note on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.